Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours (P3BEP)

UVA Tracking #
HSR220427
Principal Investigator
Brian C Belyea
Contact
Sandra Oliphant
Contact Email
Contact Phone
434.982.1091
Official Trial Title
AGCT1532: A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumors
Study Description

The Pediatric Hematology/Oncology Division at the University of Virginia is conducting a clinical research study for pediatric patients who have been diagnosed with germ cell cancer. The purpose of this study is to determine whether accelerated BEP chemotherapy is more effective than standard BEP chemotherapy in males with intermediate and poor-risk metastatic germ cell tumours.

Additional information can be found here: Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours - Full Text View - ClinicalTrials.gov (ClinicalTrials.gov Identifier: NCT 02582697)

Compensation

No Compensation